NO20051928L - Tieno [3,2-b] pyridin-6-karbonitriler og tieno [2,3-b] pyridin-5-karbonitriler som proteasekinase inhibitorer. - Google Patents

Tieno [3,2-b] pyridin-6-karbonitriler og tieno [2,3-b] pyridin-5-karbonitriler som proteasekinase inhibitorer.

Info

Publication number
NO20051928L
NO20051928L NO20051928A NO20051928A NO20051928L NO 20051928 L NO20051928 L NO 20051928L NO 20051928 A NO20051928 A NO 20051928A NO 20051928 A NO20051928 A NO 20051928A NO 20051928 L NO20051928 L NO 20051928L
Authority
NO
Norway
Prior art keywords
carbonitriles
pyridine
tieno
thieno
kinase inhibitors
Prior art date
Application number
NO20051928A
Other languages
English (en)
Norwegian (no)
Other versions
NO20051928D0 (no
Inventor
Diane Harris Boschelli
Nan Zhang
Ana Carolina Barrios Sosa
Haris Durutlic
Biqi Wu
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20051928D0 publication Critical patent/NO20051928D0/no
Publication of NO20051928L publication Critical patent/NO20051928L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20051928A 2002-11-25 2005-04-20 Tieno [3,2-b] pyridin-6-karbonitriler og tieno [2,3-b] pyridin-5-karbonitriler som proteasekinase inhibitorer. NO20051928L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42886202P 2002-11-25 2002-11-25
PCT/US2003/036206 WO2004048386A2 (en) 2002-11-25 2003-11-14 THIENO[3,2-b]PYRIDINE-6-CARBONITRILES AND THIENO[2,3-b]PYRIDINE-5-CARBONITRILES AS PROTEIN KINASE INHIBITORS

Publications (2)

Publication Number Publication Date
NO20051928D0 NO20051928D0 (no) 2005-04-20
NO20051928L true NO20051928L (no) 2005-08-19

Family

ID=32393469

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051928A NO20051928L (no) 2002-11-25 2005-04-20 Tieno [3,2-b] pyridin-6-karbonitriler og tieno [2,3-b] pyridin-5-karbonitriler som proteasekinase inhibitorer.

Country Status (20)

Country Link
US (1) US6987116B2 (de)
EP (1) EP1565474A2 (de)
JP (1) JP2006509760A (de)
KR (1) KR20050086770A (de)
CN (1) CN1714092A (de)
AR (1) AR042087A1 (de)
AU (1) AU2003290802A1 (de)
BR (1) BR0316534A (de)
CA (1) CA2502614A1 (de)
CL (1) CL2003002287A1 (de)
EC (1) ECSP055802A (de)
MX (1) MXPA05004744A (de)
NI (1) NI200500089A (de)
NO (1) NO20051928L (de)
NZ (1) NZ540104A (de)
RU (1) RU2005120018A (de)
TW (1) TW200412950A (de)
UA (1) UA81000C2 (de)
WO (1) WO2004048386A2 (de)
ZA (1) ZA200504238B (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276519B2 (en) * 2002-11-25 2007-10-02 Wyeth Thieno[3,2-b]pyridine-6-carbonitriles and thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors
FR2862647B1 (fr) * 2003-11-25 2008-07-04 Aventis Pharma Sa Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
ES2438017T3 (es) 2004-07-30 2014-01-15 Methylgene Inc. Inhibidores de la señalización del receptor del VEGF y del receptor del HGF
GB0423653D0 (en) * 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
KR101378716B1 (ko) * 2005-05-20 2014-04-10 메틸진 인코포레이티드 Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달의 억제제
AU2006313456B2 (en) 2005-05-20 2011-06-23 Methylgene Inc. Inhibitors of VEGF receptor and HGF receptor signaling
US7880004B2 (en) 2005-09-15 2011-02-01 Bristol-Myers Squibb Company Met kinase inhibitors
AR056200A1 (es) * 2005-09-27 2007-09-26 Wyeth Corp Tieno [2,3-b]piridin-5-carbonitrilos como inhibidores de proteina quinasa
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
JP2009526761A (ja) * 2006-01-30 2009-07-23 アレイ バイオファーマ、インコーポレイテッド ヘテロ二環式チオフェン化合物および使用の方法
GB0601962D0 (en) * 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
WO2007089716A2 (en) * 2006-02-01 2007-08-09 The Regents Of The University Of California Use of aminopyrimidine compounds in the treatment of immune disorders
CN101378758A (zh) * 2006-02-08 2009-03-04 惠氏公司 经由钯介导的偶联反应制备7-烯基-3氰基喹啉
JP2009539878A (ja) * 2006-06-08 2009-11-19 アレイ バイオファーマ、インコーポレイテッド キノリン化合物および使用方法
AU2007286808B2 (en) * 2006-08-21 2012-12-06 Genentech, Inc. Aza-benzofuranyl compounds and methods of use
ES2528797T3 (es) * 2006-08-21 2015-02-12 Genentech, Inc. Compuestos de aza-benzotiofenilo y métodos de uso
TW200821318A (en) * 2006-09-26 2008-05-16 Wyeth Corp Process for the preparation of 4-hydroxythieno[2,3-b]pyridine-5-carbonitriles
GB0714384D0 (en) * 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
RU2346947C1 (ru) * 2007-08-13 2009-02-20 Государственное образовательное учреждение высшего профессионального образования "Кубанский государственный технологический университет" (ГОУВПО "КубГТУ") Способ получения фурилгетарилметанов, содержащих тиено[2,3-b]пиридиновый фрагмент
PL2183254T3 (pl) * 2007-08-29 2017-10-31 Methylgene Inc Inhibitory aktywności białkowej kinazy tyrozynowej
US20090118276A1 (en) * 2007-11-02 2009-05-07 Wyeth Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors
EP2240494B1 (de) * 2008-01-21 2016-03-30 UCB Biopharma SPRL Thienopyridin-derivate als mek-hemmer
AR070317A1 (es) * 2008-02-06 2010-03-31 Osi Pharm Inc Furo (3,2-c) piridina y tieno (3,2-c) piridinas
NZ588355A (en) 2008-03-05 2012-03-30 Methylgene Inc Inhibitors of protein tyrosine kinase activity
GB0811304D0 (en) * 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
US8841462B2 (en) * 2008-07-01 2014-09-23 Robert A. Heald Bicyclic heterocycles as MEK kinase inhibitors
TW201204733A (en) 2010-06-25 2012-02-01 Kowa Co Novel condensed pyridine or condensed pyrimidine derivative, and medicinal agent comprising same
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
PE20191245A1 (es) 2013-01-15 2019-09-18 Incyte Holdings Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
KR101468207B1 (ko) * 2013-02-14 2014-12-01 한국화학연구원 신규한 싸이에노[3,2-b]피리딜 우레아 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 유로텐신-Ⅱ 수용체 활성 관련 질환의 예방 또는 치료용 약학적 조성물
EA201690458A1 (ru) 2013-08-23 2016-07-29 Инсайт Корпорейшн Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
WO2020167624A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia
SG11202108519TA (en) 2019-02-13 2021-09-29 Ptc Therapeutics Inc Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia
EP3929185A4 (de) * 2019-02-19 2023-02-15 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Stickstoffhaltige kondensierte cyclische verbindung, herstellungsverfahren dafür und verwendung davon
US11358971B2 (en) 2019-07-03 2022-06-14 H. Lundbeck A/S Prodrugs of modulators of the NMDA receptor
US11466027B2 (en) 2019-07-03 2022-10-11 H. Lundbeck A/S Modulators of the NMDA receptor
CN114269753B (zh) * 2019-09-29 2024-03-05 四川科伦博泰生物医药股份有限公司 一种含氮并环类化合物，包含其的药物组合物，其制备方法及其用途
US20240051968A1 (en) * 2021-02-05 2024-02-15 Ptc Therapeutics, Inc. Methods for treating spinocerebellar ataxia type 3
EP4483954A1 (de) * 2023-06-29 2025-01-01 Masarykova Univerzita Substituierte thieno[3,2-b pyridine als proteinkinasehemmer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US45A (en) * 1836-10-11 Machine fob shelling cokm
EP0126970A3 (de) 1983-04-27 1985-11-06 Beecham Group Plc Anxiolytische und anti-depressante Thienopyridinderivate
AR004010A1 (es) * 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
EP1028964A1 (de) * 1997-11-11 2000-08-23 Pfizer Products Inc. Thienopyrimidin- und thienopyridin-derivate als antikrebsmittel
IL142092A0 (en) * 1998-09-29 2002-03-10 American Cyanamid Co Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
JP3270834B2 (ja) * 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
GB9906566D0 (en) * 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
ES2216884T3 (es) * 1999-04-21 2004-11-01 Wyeth Holdings Corporation 3-ciano-(1.7),(1.5) y (1.8)-naftiridina sustituidas que son inhibidores de tirosina-quinasas.
DK1242382T3 (da) * 1999-12-29 2007-05-07 Wyeth Corp Tricycliske proteinkinaseinhibitorer
AR035851A1 (es) * 2000-03-28 2004-07-21 Wyeth Corp 3-cianoquinolinas, 3-ciano-1,6-naftiridinas y 3-ciano-1,7-naftiridinas como inhibidoras de proteina quinasas
BR0111377A (pt) * 2000-06-06 2003-06-03 Pfizer Prod Inc Derivados de tiofeno úteis como agentes anticancerìgenos
US20020004511A1 (en) * 2000-06-28 2002-01-10 Luzzio Michael Joseph Thiophene derivatives useful as anticancer agents
EP1337513A1 (de) * 2000-11-02 2003-08-27 AstraZeneca AB 4-substituierte chinoline als antitumormittel
US20040248906A1 (en) 2001-08-10 2004-12-09 Donato Nicholas J Use of c-src inhibitors alone or in combination with st1571 for the treatment of leukaemia

Also Published As

Publication number Publication date
WO2004048386A2 (en) 2004-06-10
US6987116B2 (en) 2006-01-17
CN1714092A (zh) 2005-12-28
AR042087A1 (es) 2005-06-08
ZA200504238B (en) 2009-09-30
BR0316534A (pt) 2005-10-04
UA81000C2 (en) 2007-11-26
JP2006509760A (ja) 2006-03-23
WO2004048386A3 (en) 2004-10-07
NI200500089A (es) 2006-01-11
NZ540104A (en) 2007-05-31
AU2003290802A1 (en) 2004-06-18
TW200412950A (en) 2004-08-01
RU2005120018A (ru) 2006-05-10
ECSP055802A (es) 2005-08-11
CA2502614A1 (en) 2004-06-10
WO2004048386A9 (en) 2005-07-14
NO20051928D0 (no) 2005-04-20
MXPA05004744A (es) 2005-08-03
US20040138251A1 (en) 2004-07-15
KR20050086770A (ko) 2005-08-30
EP1565474A2 (de) 2005-08-24
CL2003002287A1 (es) 2005-01-14

Similar Documents

Publication Publication Date Title
NO20051928L (no) Tieno [3,2-b] pyridin-6-karbonitriler og tieno [2,3-b] pyridin-5-karbonitriler som proteasekinase inhibitorer.
SG145744A1 (en) Process for the preparation of 4-amino-3- quinolinecarbonitriles
YU17003A (sh) Spiroheterociklični nitrili upotrebljivi kao reverzibilni inhibitori cisteinskih proteaza
NO20026030D0 (no) Pyrrolo[2,3-d]pyramidin-forbindelser som immunosuppresive midler
EP1467735A4 (de) Polymorphe von clopidogrel-hydrogensulfat
WO2002102313A3 (en) Pyrimidine inhibitors of phosphodiesterase (pde) 7
YU17402A (sh) Nova spiroheterociklična jedinjenja upotrebljiva kao reverzibilni inhibitori cisteinskih proteaza
ATE485300T1 (de) Als aurora-kinase-inhibitoren nutzbare thienopyrimidine
WO2002087513A3 (en) Fused heterocyclic inhibitors of phosphodiesterase (pde) 7
IL152586A0 (en) Serine protease inhibitors
EP1479684A4 (de) Thienopyrimidine, verfahren zu deren herstellung und deren verwendung
AU2003237305A1 (en) Process of preparation of olanzapine form i
PL362922A1 (en) Method for the production of 4,6-diaminopyrimido[5,4-d]pyrimidines
WO2004043379A3 (en) Chemical compounds
NO20065489L (no) Tieno[3,2-b]pyridin-6-karbonitriler som protein-kinase inhibitorer
AU2003219661A1 (en) Thieno (3, 2-b) pyridones as antiviral compounds
WO2002076396A3 (en) Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
DK1501838T3 (da) Fremgangsmåde til fremstilling af clopidogrel
PT1469853E (pt) Utilização de 4-(2-fluorofenil)-6-metil-2-(1-piperazinil)-tieno[2,3-d]pirimidina para o tratamento da incontinência urinária
EP1436279A4 (de) Chemische verbindungen
MXPA02003042A (es) Proceso para prevenir formacion de incrustaciones.
DK1307460T3 (da) Fremgangsmåde til fremstilling af imidazo [1,2-c][2,3]benzodiazepiner og mellemprodukter ved fremstilling af disse
HU0501046D0 (en) Process for the preparation of olanzapine
UA86772C2 (en) Process for the preparation of the polymorph form of methyl (s)-(+)-(2-chlorophenyl)-2-(6,7-dihydro-4h-thieno[3,2-c]pyridine-5-yl-acetate hydrogensulfate
AU2002315978A1 (en) Method for target-tracking of objects

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application